Farxiga at $1,323 on a $0-Premium Part D Plan vs $1,273 on a $34/Month Plan: How Brand vs. Generic Flips the Cheapest Rural Plan in 2026
You take Eliquis (apixaban) 5mg twice a day, Farxiga (dapagliflozin) 10mg once a day, and generic lisinopril 20mg once a day. You live in a rural parish where, according to reporting from KFF Health News on Louisiana's rural health tech push ("States Bet Big on Rural Health Startups, With a Silicon Valley Twist"), the state is now paying startups $250,000 to $3 million to solve a problem that used to have a simple answer: a doctor's office and a pharmacy within driving distance. More than 200 companies pitched Louisiana to fill gaps left by vanished rural hospitals and closed pharmacies. That's not background noise for a Part D shopper — it's the whole ballgame, because your pharmacy network access is doing as much work on your annual drug bill as your formulary tier is.
Here's what that actually means in dollars, using your real drug list against two 2026 Part D plans.
Why your ZIP code changes the math before the drugs even do
Most Part D comparisons stop at premium versus deductible. But if you live somewhere the local retail pharmacy is the only one in-network — which is increasingly the reality in the rural counties Louisiana is trying to patch with startup money — you're often stuck paying standard coinsurance instead of the lower preferred-network rate that a national plan's mail-order or big-chain network offers. That's a real cost difference, not a convenience issue. Below, "Plan A" reflects a $0-premium regional PDP with a thin rural network. "Plan B" reflects a $34/month national plan built around a mail-order preferred pharmacy.
Gross annual drug cost, no insurance applied:
| Drug | Dose | Annual Cost |
|---|---|---|
| Eliquis (apixaban) | 5mg twice daily | $2,772 (IRA-negotiated $231/month price applies nationally) |
| Farxiga (dapagliflozin), brand | 10mg once daily | $605 |
| Lisinopril, generic | 20mg once daily | $48 |
| Total | $3,425 |
Scenario 1: Brand-name Farxiga — the premium plan wins
| Plan A: Bayou Value Rx ($0 premium) | Plan B: National Saver Rx ($34/month) | |
|---|---|---|
| Annual premium | $0 | $408 |
| Deductible (tiers 3+) | $590 | $350 |
| Tier 1 generic (lisinopril) | $3/mo copay, deductible waived → $36/yr | $0 copay, deductible waived |
| Tier 3 coinsurance (Eliquis + Farxiga, post-deductible) | 25% at sole in-network rural pharmacy | 17% at preferred mail-order pharmacy |
| Cost-sharing after deductible | $696.75 | $514.59 |
| Total annual cost | $1,322.75 | $1,272.59 |
With brand-name Farxiga in the mix, Plan B wins by about $50 a year — even after you account for the $408 premium — because the preferred-pharmacy coinsurance rate (17% versus 25%) and lower deductible do more work than the $0 premium saves you. This is the kind of analysis Pelandri runs for you across every plan in your ZIP code, so you don't have to build this spreadsheet by hand for your own drug list.
Scenario 2: Switch to generic dapagliflozin — the $0-premium plan wins
Dapagliflozin's generic entered many 2026 formularies at a preferred-generic tier, typically priced around $180 a year instead of Farxiga's $605 brand price. That single substitution changes your total drug spend from $3,425 to $3,000 — and it changes which plan is cheapest.
| Plan A: Bayou Value Rx ($0 premium) | Plan B: National Saver Rx ($34/month) | |
|---|---|---|
| Annual premium | $0 | $408 |
| Deductible applied | $590 (tiers 2–5) | $350 (tiers 3–5 only; tier 2 waived) |
| Tier 1 generic (lisinopril) | $36/yr | $0 |
| Tier 2 generic (dapagliflozin) | Subject to deductible, then coinsurance | $120/yr flat copay, no deductible |
| Tier 3 coinsurance (Eliquis) | 25% post-deductible | 17% post-deductible |
| Total annual cost | $1,216.50 | $1,289.74 |
Once Farxiga becomes generic, Plan A — the $0-premium plan with the worse coinsurance rate — becomes about $73 cheaper for the year, because there's simply less total drug cost left over for that 25% coinsurance to apply to, and the $408 premium on Plan B no longer has a big brand-drug bill to offset. The formulary tier and brand/generic status of a single drug on your list can flip the cheapest plan entirely. That's the exact dynamic we walked through with rosuvastatin and Crestor in how formulary tiers decide your Part D bill, and it shows up again here with Farxiga.
If you want to see this run against your actual formulary status for Farxiga — brand or generic, whichever your prescriber has you on — you can model this for your specific situation at Pelandri.
Neither plan hits the $2,000 cap here — but add one more drug and that changes
Notice that in both scenarios, total out-of-pocket cost stays under Medicare's 2026 out-of-pocket cap of $2,000. That means every dollar of plan-design difference — deductible size, coinsurance rate, pharmacy network — flows straight to your bill. But if this same beneficiary were also on insulin or a specialty biologic, they'd likely blow through the $2,000 cap by mid-year on both plans, and at that point the rest of the year is $0 regardless of which plan they picked. We modeled that dynamic in detail with Eliquis, Farxiga, and Symbicort in why the donut hole being gone still leaves a $468 swing between plans. The lesson: the fewer or cheaper your drugs, the more plan design matters. The more expensive your drug list, the more premium and network access matter, because you'll hit the cap on both plans anyway and the premium becomes the deciding factor.
The Medicaid work requirement risk hiding in your Extra Help eligibility
KFF Health News' reporting on a cancer survivor who lost Medicaid disability coverage ("A Cancer Survivor Hoped To Work — Then She Lost Her Medicaid Disability Coverage") describes states struggling to determine, under new Medicaid work requirements, who's sick enough to be excused from proving employment. That redetermination churn isn't limited to Medicaid disability categories — it's the same administrative machinery that reviews eligibility for the Extra Help (LIS) program and Medicare Savings Programs that many dual-eligible Part D enrollees rely on. If you or a parent are on Extra Help and get a redetermination notice this fall, don't assume it's routine. Losing that status mid-year can turn a $0-premium, low-copay plan into full-price coinsurance overnight. We laid out exactly what that swing looks like for a caregiver managing someone else's prescriptions in Eliquis and Jardiance with and without Extra Help under the new Medicaid work requirement — worth reading before you assume this year's LIS status carries into 2026 unchanged.
Aging into Medicare after losing your ACA subsidy — the sticker shock is real, but so is the fix
KFF Health News' piece on Georgia's 14th District ("Rising Healthcare Costs Have Hit Georgia's Most Conservative District") documents what happens when enhanced ACA marketplace subsidies expire: people either pay dramatically more for the same coverage or go uninsured. If you're 63 or 64 and watching your marketplace premium climb before you age into Medicare, it's tempting to assume Part D will bring more of the same sticker shock. It usually doesn't work that way — Part D premiums and cost-sharing are governed by an entirely different set of rules than ACA marketplace plans, and the plan you land on can vary by hundreds of dollars a year for the exact same drug list depending on formulary placement and pharmacy network, not income-based subsidy phaseouts. If you're approaching 65 and trying to plan your transition off marketplace coverage, turning 65 with Eliquis, metformin, and atorvastatin walks through how that first Part D comparison actually works.
Watch for "skimpy" plans that don't count as creditable coverage
A pending lawsuit against the Department of Labor, reported by KFF Health News ("Outcome of Suit Against Department of Labor Could Boost Skimpy Employer Health Plans"), centers on a marketing company trying to redefine app users who agree to have their internet activity tracked as "employees" eligible for a limited-benefit health plan — the kind of plan that's exempt from many ACA and state consumer protections. If that case expands access to these association-style plans, more people approaching Medicare age may find themselves on coverage that looks like insurance but doesn't meet the "creditable coverage" bar Medicare uses to waive the Part D late enrollment penalty. That penalty compounds for every month you go without creditable drug coverage after your Initial Enrollment Period ends, and it never goes away. Before you rely on any employer-adjacent or gig-platform health plan to bridge you to 65, confirm in writing that it's creditable — don't assume it, and don't let a skimpy plan cost you a permanent premium surcharge on top of whatever plan comparison you eventually do.
What to actually do before December 7
The math above isn't a general rule — it's specific to this drug list, this deductible structure, and this pharmacy network. Change one drug from brand to generic, change your ZIP code's pharmacy options, or add a fourth medication, and the cheapest plan can flip again, sometimes by hundreds of dollars. That's the whole reason a "just pick the $0-premium plan" or "just pick the plan you had last year" default fails so often — Medicare's own data shows the same three-drug list can vary by 20% or more in total annual cost across plans available in a single county.
Before Open Enrollment closes, pull your actual drug list — names, dosages, and whether each one is brand or generic on your current formulary — and run it against every plan sold in your ZIP code, not just the two or three that show up first in Medicare Plan Finder. That's exactly the comparison Pelandri is built to run: your drugs, your pharmacy, your ZIP code, translated into a real annual total instead of a monthly premium that hides the rest of the story.
Data behind this post
The figures above are computed from the product's own reference tables, last refreshed 2026-04-15:
- 210 rows from aca-subsidy-params
- 1,080 rows from bls-medical-cpi
- 6,286 rows from census-acs-health-coverage
- 4,080 rows from cms-marketplace-plans
- 400 rows from employer-plan-data
- 30 rows from plan-defaults
Sources
- States Bet Big on Rural Health Startups, With a Silicon Valley Twist — KFF Medicare
- Outcome of Suit Against Department of Labor Could Boost Skimpy Employer Health Plans — KFF Medicare
- Rising Healthcare Costs Have Hit Georgia’s Most Conservative District. But Its Politics Are Unlikely To Change. — KFF Medicare
- A Cancer Survivor Hoped To Work — Then She Lost Her Medicaid Disability Coverage — KFF Medicare
- A Generation of Kids Suffer as Trump Destabilizes Immigrant Families — KFF Medicare